Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12
University of Texas MD Anderson Cancer Center, Medical Devices Deals, 2012 to YTD 2018 13
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deal Details 22
Venture Financing 22
OncoResponse Raises Additional USD3 Million in Series A Financing 22
OncoResponse Raises USD9.5 Million in Series A Financing 24
Partnerships 26
Immatics US Enters into Licensing Agreement with MD Anderson 26
Inflection Biosciences Enters into Research Collaboration with MD Anderson Cancer Center 27
PanTher Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 28
Cyclacel Pharma Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 29
Jazz Pharma and MD Anderson Cancer Center Enter into Agreement 30
Genprex Enters into Research Agreement with University of Texas MD Anderson 31
Bayer and MD Anderson Cancer Center Enter into Agreement 32
Amgen and MD Anderson Enter Two Collaboration Agreements 33
Polaris Enters into Agreement with University of Texas MD Anderson Cancer Center 34
Humanigen Enters into Research Agreement with MD Anderson Cancer Center 35
Nanobiotix Enters into Research Agreement with University of Texas MD Anderson Cancer Center 36
The University of Texas MD Anderson Cancer Center Forms Joint Venture with Berkeley Lights 37
Seres Therapeutics to Enter into Partnership Agreement with MD Anderson and Parker Institute 38
Oncoceutics and University of Texas MD Anderson Cancer Center Enter into Research Agreement 39
University of Texas MD Anderson Cancer Center Forms Joint Venture with BridgeBio Pharma 40
University of Texas MD Anderson Cancer Center Enters into Partnership with Pfizer 41
ConverGene Enters into Research Agreement with MD Anderson Cancer Center 42
University of Texas MD Anderson and Daiichi Sankyo Enter into Research Agreement 43
Kiromic Enters into Agreement with University of Texas MD Anderson Cancer Center 44
Hitachi Medical Systems America and University of Texas MD Anderson Cancer Center Enter into Research Agreement 45
Lion Biotech Enters into Agreement with MD Anderson Cancer Center 46
Medicenna Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 47
Genprex Enters into Option Agreeement with University of Texas MD Anderson Cancer Center 48
University of Texas MD Anderson Cancer Center and Deerfield Management Form Joint Venture 49
EMD Serono Enters into Agreement with University of Texas MD Anderson Cancer Center 50
Affimed Enters into Agreement with University of Texas MD Anderson Cancer Center 51
Adaptimmune Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 52
Golden Meditech and MD Anderson to Form Joint Venture 53
Moleculin Biotech Expands its Research Agreement with University of Texas MD Anderson Cancer Center 54
BioLineRx to Enter into Agreement with University of Texas MD Anderson Cancer Center 55
Hitachi Chemical and University of Texas MD Anderson Cancer Center Enter into Agreement 56
Bristol-Myers Squibb and University of Texas MD Anderson Enter into Research Agreement 57
MorphoSys Partners with University of Texas MD Anderson Cancer Center 58
Ionis Pharma Partners with University of Texas MD Anderson Cancer Center 59
Jiangsu Hengrui Medicine Enters into Research Agreement with University of Texas MD Anderson Cancer Center 60
Helsinn Healthcare Partners with University of Texas MD Anderson Cancer Center 61
Novocure Enters into Research Agreement with MD Anderson Cancer Center 62
Bio-Path Enters into Research Agreement with University of Texas MD Anderson Cancer Center 63
Kiromic Enters into Agreement with University of Texas MD Anderson Cancer Center 64
AbbVie Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 65
Mologen Enters into Agreement with The University of Texas MD Anderson Cancer Center 66
DelMar Pharma Enters into Agreement with University of Texas MD Anderson Cancer Center 67
Enumeral Biomedical Enters into R&D Agreement with University of Texas MD Anderson Cancer Center 68
X-Chem Enters into Agreement with University of Texas MD Anderson Cancer Center 69
Kymab Enters into Agreement with University of Texas MD Anderson 70
Karus Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 71
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 72
Boehringer Ingelheim Enters into Co-Development Agreement with MD Anderson Cancer Center 73
ImmunoCellular Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 74
CytomX Therapeutics Enters into Agreement with University of Texas M. D. Anderson Cancer Center 75
Molecular Templates Enters into Research Agreement with MD Anderson Cancer Center 76
University of Texas MD Anderson Cancer Center and Theraclone Sciences Form Joint Venture 77
MD Anderson and Theraclone Sciences Form Joint Venture 78
The University of Texas MD Anderson Cancer Center, Cayman Chemical and Fannin Innovation Studio Form Joint Venture 79
Cellectis Enters into R&D Agreement with The University of Texas MD Anderson Cancer Center 80
Merck Enters into Research Agreement with University of Texas MD Anderson Cancer Center 81
Idera Pharma Enters into Research Agreement with University of Texas 82
Concord Medical Enters into Co-Development Agreement with MD Anderson 83
Astellas Pharma Enters into Option Agreement with MD Anderson 84
Angle Enters into Agreement with MD Anderson Cancer Center 85
AstraZeneca Enters into Research Agreement with University of Texas MD Anderson Cancer Center 86
Amgen Enters into Research Agreement with MD Anderson 87
Genprex Enters into Option Agreeement with University of Texas MD Anderson Cancer Center, for Oncoprex therapy 88
Senior Scientific Renews Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 89
GlaxoSmithKline Enters Into Agreement With University of Texas MD Anderson Cancer Center For Immunotherapy Drugs 90
MedImmune Enters Research Agreement With University of Texas MD Anderson 91
Genprex Enters into Agreement with University of Texas MD Anderson Cancer Center 92
University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 93
Pfizer Enters Into Development Agreement With University of Texas MD Anderson Cancer Center For Cancer Immunotherapy 94
Cooper University Forms Joint Venture With University of Texas MD Anderson Cancer Center 95
Boston Strategics Enters Into Agreement With University of Texas MD Anderson Cancer Center For Oncology Drug Development 96
Cellceutix Enters Into Agreement With University of Texas MD Anderson Cancer Center For Kevetrin Drug 97
University of Texas Enters Into Co-Development Agreement With Hospital Israelita Albert Einstein 99
Licensing Agreements 100
Ipsen Enters into Licensing Agreement with MD Anderson 100
Spectrum Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer 101
Heidelberg Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 102
Moleculin Biotech Enters into Licensing Agreement with MD Anderson Cancer Center 103
Cellenkos Enters Licensing Agreement with University of Texas MD Anderson Cancer Center 104
Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 105
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 106
Jounce Therapeutics Amends Licensing Agreement for JTX-2011 108
GlaxoSmithKline Enters Into Licensing Agreement With University of Texas MD Anderson Cancer Center For Antibodies 110
Codiak BioSciences Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 111
University of Texas MD Anderson Cancer Center – Key Competitors 112
University of Texas MD Anderson Cancer Center – Key Employees 113
University of Texas MD Anderson Cancer Center – Locations And Subsidiaries 114
Head Office 114
Other Locations & Subsidiaries 114
Joint Venture 115
Recent Developments 117
Strategy And Business Planning 117
Mar 07, 2018: MD Anderson and Berkeley Lights Launch Optera Therapeutics to Accelerate Development of Cell Therapies for Cancer 117
Jan 11, 2017: MD Anderson and Deerfield Management create Vescor to develop novel therapeutics based on inhibiting autophagy for treatment of specific cancers 118
Government and Public Interest 119
Sep 10, 2018: Study links BAP1 protein to tumor suppression in kidney, eye, bile duct and mesothelioma cancers 119
Aug 24, 2018: $50 million awarded by CPRIT to MD Anderson and its projects 120
Aug 06, 2018: Comprehensive CAR t-cell therapy pediatric guidelines developed by MD Anderson in collaboration with the pediatric acute lung injury and sepsis investigators network 121
Jun 26, 2018: Pancreatic Cancer Action Network Funds Innovative Scientists through Research Grants Program 122
May 16, 2018: Self-reporting with sensor and mobile technology may reduce symptom burden for head and neck cancer patients undergoing radiation treatment 123
May 14, 2018: New approach to cancer research aims to accelerate studies and reduce cost 124
Apr 16, 2018: Boosting T cell “memory” may result in longer-lasting and effective responses for patients treated with checkpoint blockade immunotherapies 125
Mar 02, 2018: Deeper look at biopsy exposes mutation ready to ambush drug combination 126
Jan 17, 2018: Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma 128
Nov 02, 2017: Lung Cancer Research Foundation Awards $1.6 Million in Research Grants 130
Oct 16, 2017: PROMETRIKA to Coordinate Second Phase I Trial for MD Anderson’s Institute for Applied Cancer Science 132
Aug 24, 2017: Research reveals how estrogen regulates gene expression 133
Jun 07, 2017: Innovative therapy strategy for pancreatic cancer uses engineered exosomes targeting mutated KRAS gene 134
Jun 02, 2017: Combination therapy targets genetic mutation found in many cancers 135
Feb 23, 2017: Study reveals PGK1 enzyme as therapeutic target for deadliest brain cancer 136
Feb 10, 2017: U.S. Scientists Receive Inaugural $87 Million Grand Challenge Awards To Accelerate Global Progress To Beat Cancer Sooner 137
Product News 138
May 17, 2018: Researchers test flexible cancer research model 138
May 03, 2018: Preclinical MD Anderson study suggests ARID1a may be useful biomarker for immunotherapy 139
Feb 06, 2017: Researchers identify synthetic essentiality as novel approach for locating cancer therapy targets 141
Other Significant Developments 142
May 09, 2018: An AI Oncologist to Help Cancer Patients Worldwide 142
Appendix 144
Methodology 144
About GlobalData 144
Contact Us 144
Disclaimer 144
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Key Facts, 2017 2
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
University of Texas MD Anderson Cancer Center, Deals By Therapy Area, 2012 to YTD 2018 12
University of Texas MD Anderson Cancer Center, Medical Devices Deals, 2012 to YTD 2018 13
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
OncoResponse Raises Additional USD3 Million in Series A Financing 22
OncoResponse Raises USD9.5 Million in Series A Financing 24
Immatics US Enters into Licensing Agreement with MD Anderson 26
Inflection Biosciences Enters into Research Collaboration with MD Anderson Cancer Center 27
PanTher Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 28
Cyclacel Pharma Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 29
Jazz Pharma and MD Anderson Cancer Center Enter into Agreement 30
Genprex Enters into Research Agreement with University of Texas MD Anderson 31
Bayer and MD Anderson Cancer Center Enter into Agreement 32
Amgen and MD Anderson Enter Two Collaboration Agreements 33
Polaris Enters into Agreement with University of Texas MD Anderson Cancer Center 34
Humanigen Enters into Research Agreement with MD Anderson Cancer Center 35
Nanobiotix Enters into Research Agreement with University of Texas MD Anderson Cancer Center 36
The University of Texas MD Anderson Cancer Center Forms Joint Venture with Berkeley Lights 37
Seres Therapeutics to Enter into Partnership Agreement with MD Anderson and Parker Institute 38
Oncoceutics and University of Texas MD Anderson Cancer Center Enter into Research Agreement 39
University of Texas MD Anderson Cancer Center Forms Joint Venture with BridgeBio Pharma 40
University of Texas MD Anderson Cancer Center Enters into Partnership with Pfizer 41
ConverGene Enters into Research Agreement with MD Anderson Cancer Center 42
University of Texas MD Anderson and Daiichi Sankyo Enter into Research Agreement 43
Kiromic Enters into Agreement with University of Texas MD Anderson Cancer Center 44
Hitachi Medical Systems America and University of Texas MD Anderson Cancer Center Enter into Research Agreement 45
Lion Biotech Enters into Agreement with MD Anderson Cancer Center 46
Medicenna Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 47
Genprex Enters into Option Agreeement with University of Texas MD Anderson Cancer Center 48
University of Texas MD Anderson Cancer Center and Deerfield Management Form Joint Venture 49
EMD Serono Enters into Agreement with University of Texas MD Anderson Cancer Center 50
Affimed Enters into Agreement with University of Texas MD Anderson Cancer Center 51
Adaptimmune Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 52
Golden Meditech and MD Anderson to Form Joint Venture 53
Moleculin Biotech Expands its Research Agreement with University of Texas MD Anderson Cancer Center 54
BioLineRx to Enter into Agreement with University of Texas MD Anderson Cancer Center 55
Hitachi Chemical and University of Texas MD Anderson Cancer Center Enter into Agreement 56
Bristol-Myers Squibb and University of Texas MD Anderson Enter into Research Agreement 57
MorphoSys Partners with University of Texas MD Anderson Cancer Center 58
Ionis Pharma Partners with University of Texas MD Anderson Cancer Center 59
Jiangsu Hengrui Medicine Enters into Research Agreement with University of Texas MD Anderson Cancer Center 60
Helsinn Healthcare Partners with University of Texas MD Anderson Cancer Center 61
Novocure Enters into Research Agreement with MD Anderson Cancer Center 62
Bio-Path Enters into Research Agreement with University of Texas MD Anderson Cancer Center 63
Kiromic Enters into Agreement with University of Texas MD Anderson Cancer Center 64
AbbVie Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 65
Mologen Enters into Agreement with The University of Texas MD Anderson Cancer Center 66
DelMar Pharma Enters into Agreement with University of Texas MD Anderson Cancer Center 67
Enumeral Biomedical Enters into R&D Agreement with University of Texas MD Anderson Cancer Center 68
X-Chem Enters into Agreement with University of Texas MD Anderson Cancer Center 69
Kymab Enters into Agreement with University of Texas MD Anderson 70
Karus Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 71
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 72
Boehringer Ingelheim Enters into Co-Development Agreement with MD Anderson Cancer Center 73
ImmunoCellular Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 74
CytomX Therapeutics Enters into Agreement with University of Texas M. D. Anderson Cancer Center 75
Molecular Templates Enters into Research Agreement with MD Anderson Cancer Center 76
University of Texas MD Anderson Cancer Center and Theraclone Sciences Form Joint Venture 77
MD Anderson and Theraclone Sciences Form Joint Venture 78
The University of Texas MD Anderson Cancer Center, Cayman Chemical and Fannin Innovation Studio Form Joint Venture 79
Cellectis Enters into R&D Agreement with The University of Texas MD Anderson Cancer Center 80
Merck Enters into Research Agreement with University of Texas MD Anderson Cancer Center 81
Idera Pharma Enters into Research Agreement with University of Texas 82
Concord Medical Enters into Co-Development Agreement with MD Anderson 83
Astellas Pharma Enters into Option Agreement with MD Anderson 84
Angle Enters into Agreement with MD Anderson Cancer Center 85
AstraZeneca Enters into Research Agreement with University of Texas MD Anderson Cancer Center 86
Amgen Enters into Research Agreement with MD Anderson 87
Genprex Enters into Option Agreeement with University of Texas MD Anderson Cancer Center, for Oncoprex therapy 88
Senior Scientific Renews Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 89
GlaxoSmithKline Enters Into Agreement With University of Texas MD Anderson Cancer Center For Immunotherapy Drugs 90
MedImmune Enters Research Agreement With University of Texas MD Anderson 91
Genprex Enters into Agreement with University of Texas MD Anderson Cancer Center 92
University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 93
Pfizer Enters Into Development Agreement With University of Texas MD Anderson Cancer Center For Cancer Immunotherapy 94
Cooper University Forms Joint Venture With University of Texas MD Anderson Cancer Center 95
Boston Strategics Enters Into Agreement With University of Texas MD Anderson Cancer Center For Oncology Drug Development 96
Cellceutix Enters Into Agreement With University of Texas MD Anderson Cancer Center For Kevetrin Drug 97
University of Texas Enters Into Co-Development Agreement With Hospital Israelita Albert Einstein 99
Ipsen Enters into Licensing Agreement with MD Anderson 100
Spectrum Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer 101
Heidelberg Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 102
Moleculin Biotech Enters into Licensing Agreement with MD Anderson Cancer Center 103
Cellenkos Enters Licensing Agreement with University of Texas MD Anderson Cancer Center 104
Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 105
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 106
Jounce Therapeutics Amends Licensing Agreement for JTX-2011 108
GlaxoSmithKline Enters Into Licensing Agreement With University of Texas MD Anderson Cancer Center For Antibodies 110
Codiak BioSciences Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 111
University of Texas MD Anderson Cancer Center, Key Competitors 112
University of Texas MD Anderson Cancer Center, Key Employees 113
University of Texas MD Anderson Cancer Center, Other Locations 114
University of Texas MD Anderson Cancer Center, Subsidiaries 115
University of Texas MD Anderson Cancer Center, Joint Venture 115
List of Figures
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 10
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12
University of Texas MD Anderson Cancer Center, Medical Devices Deals, 2012 to YTD 2018 13
